Unicycive Therapeutics (UNCY) Change in Cash (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Change in Cash data on file, last reported at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 228.24% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $17.6 million (up 160.36% YoY), and the FY2025 full-year result was $3.1 million, down 81.41% from the prior year.
• Change in Cash for Q1 2026 stood at $8.2 million, up from -$13.5 million in the prior quarter.
• Across five years, Change in Cash topped out at $39.2 million in Q1 2024 and bottomed at -$13.5 million in Q4 2025.
• The 5-year median for Change in Cash is -$4.5 million (2023), against an average of $1.2 million.
• The widest annual swing landed in 2022, when Change in Cash sank 2112.93%; it then soared 906.93% in 2023.
• A 5-year view of Change in Cash shows it stood at -$6.6 million in 2022, then rose by 29.15% to -$4.6 million in 2023, then slumped by 33.61% to -$6.2 million in 2024, then sank by 117.52% to -$13.5 million in 2025, then soared by 160.55% to $8.2 million in 2026.
• The last three Change in Cash figures came in at $8.2 million (Q1 2026), -$13.5 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.

Peer Comparison